> According to a report in ABC News, a landmark new study called MEOW-1 is being launched by San Francisco-based biopharmaceutical company Okava to test a GLP-1 medication on up to 50 overweight cats. A miniature implant, labeled OKV-119, will administer GLP-1 medication to cats in this study continuously for up to six months.
> Okava CEO Michael Klotsman claims the company will seek FDA approval for the product between 2027 and 2028.
> According to a report in ABC News, a landmark new study called MEOW-1 is being launched by San Francisco-based biopharmaceutical company Okava to test a GLP-1 medication on up to 50 overweight cats. A miniature implant, labeled OKV-119, will administer GLP-1 medication to cats in this study continuously for up to six months.
> Okava CEO Michael Klotsman claims the company will seek FDA approval for the product between 2027 and 2028.